Day J H, Farr R S
Immunology. 1966 Dec;11(6):571-88.
Nine adult rabbits averaging 2.55 kg were each given 1.275 g bovine serum albumin (BSA Fraction V) 6 days weekly for a period of 66 days and rechallenged with 50 mg BSA or human serum albumin (HSA) 139 days after the last injection of BSA. The sera from all rabbits were studied each week for concentrations of circulating BSA and for capacity to bind I-labelled BSA or HSA (IBSA or IHSA). Some sera were also studied after fractionation on Sephadex G-200 columns to remove the BSA which had been present . Serum levels of BSA were determined and the binding studies performed using variations of the ammonium sulphate method to detect I* antigen—antibody complexes. Some sera were also studied by radioimmunoelectrophoresis. The observed steady-state serum levels of circulating BSA during the daily infusions were substantially less than the theoretical concentrations. In addition, the measured BSA levels were particularly low throughout two periods of the experiment. The first occurred between days 14 and 35 when the rabbits had significant proteinuria and the second between days 45 and 66 when maximum antibody activity was observed. Following cessation of infusions, BSA disappeared from the circulation with a 5.5 day half-life. Binding of IBSA was not detected in whole serum but was measurable between days 14 and 165 after fractionation by gel filtration with Sephadex G-200 to remove the unlabelled BSA. In contrast, Sephadex filtration was not required to demonstrate IHSA binding in whole serum between days 14 and 198, even in the presence of excess unlabelled BSA. The immunological specificities of the antibodies present during immunological paralysis' to BSA were characterized by comparing the effectiveness of graded amounts of unlabelled BSA or HSA to inhibit the I*BSA and I*HSA binding. The binding specificities of sera during
immunological paralysis' were found to be similar in certain respects but distinctly different in others from either normally produced anti-BSA or anti-HSA. Rechallenge with 50 mg HSA on day 139 produced significant IHSA binding but only slight IBSA binding. Specificity studies on these antibodies revealed characteristics more typical of the normally produced anti-HSA than were observed during immunological paralysis'. However, some characteristics of normally produced anti-BSA remained. Rechallenge with BSA produced significant binding of either I*BSA or I*HSA, and in some cases both. Specificity studies of these antibodies revealed more of the characteristics of normally produced anti-BSA than were observed prior to rechallenge but some of the characteristics of normally produced anti-HSA remained. These results indicate that rabbits receiving large daily injections of BSA are
immunologically suppressed' rather than immunologically paralysed' to BSA. A hypothesis is presented to explain the coexistence of BSA and antibodies having the I* antigen binding characteristics observed in the serum of these
immunologically suppressed' rabbits.
9只成年兔,平均体重2.55千克,每周6天,每天给予1.275克牛血清白蛋白(V组分牛血清白蛋白),持续66天。在最后一次注射牛血清白蛋白139天后,用50毫克牛血清白蛋白或人血清白蛋白(HSA)对兔子进行再次攻击。每周对所有兔子的血清进行研究,检测循环牛血清白蛋白的浓度以及结合碘标记牛血清白蛋白或人血清白蛋白(IBSA或IHSA)的能力。部分血清在经Sephadex G - 200柱分级分离以去除已存在的牛血清白蛋白后也进行了研究。测定血清中牛血清白蛋白的水平,并采用硫酸铵法的不同变体进行结合研究,以检测I抗原 - 抗体复合物。部分血清还通过放射免疫电泳进行了研究。在每日输注期间观察到的循环牛血清白蛋白的稳态血清水平显著低于理论浓度。此外,在实验的两个阶段中,测得的牛血清白蛋白水平特别低。第一个阶段出现在第14天至35天之间,此时兔子出现明显的蛋白尿;第二个阶段出现在第45天至66天之间,此时观察到最大抗体活性。输注停止后,牛血清白蛋白从循环中消失,半衰期为5.5天。在全血清中未检测到IBSA的结合,但在用Sephadex G - 200进行凝胶过滤以去除未标记的牛血清白蛋白后,在第14天至165天之间可检测到其结合。相比之下,即使存在过量未标记的牛血清白蛋白,在第14天至198天之间,无需Sephadex过滤即可在全血清中证明IHSA的结合。通过比较不同量的未标记牛血清白蛋白或人血清白蛋白抑制IBSA和IHSA结合的效果,对“免疫麻痹”期间存在的针对牛血清白蛋白的抗体的免疫特异性进行了表征。发现“免疫麻痹”期间血清的结合特异性在某些方面相似,但在其他方面与正常产生的抗牛血清白蛋白或抗人血清白蛋白明显不同。在第139天用50毫克人血清白蛋白再次攻击产生了显著的IHSA结合,但只有轻微的IBSA结合。对这些抗体的特异性研究显示,其特征比“免疫麻痹”期间观察到的更典型地属于正常产生的抗人血清白蛋白,但仍保留了一些正常产生的抗牛血清白蛋白的特征。用牛血清白蛋白再次攻击产生了显著的IBSA或IHSA结合,在某些情况下两者都有。对这些抗体的特异性研究显示,与再次攻击前相比,更多地具有正常产生的抗牛血清白蛋白的特征,但仍保留了一些正常产生的抗人血清白蛋白的特征。这些结果表明,每天接受大量牛血清白蛋白注射的兔子对牛血清白蛋白是“免疫抑制”而非“免疫麻痹”。本文提出了一个假设,以解释在这些“免疫抑制”兔子血清中观察到的牛血清白蛋白与具有I抗原结合特性的抗体共存的现象。